NRX-1074 in Early Course Schizophrenia

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study seeks to examine the effectiveness of NRX-1074 in the treatment of negative symptoms and cognition in schizophrenia compared to other agents at the glycine site which have demonstrated inconsistent results for negative symptoms. In addition to testing efficacy, we will examine the time course of response of symptoms as well as any effects on memory consolidation.

Key facts

Study ID

NCT02603458

Run by

NYU Langone Health

People needed

0

Last updated by the study team

2016-02-05

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-50
• Diagnosis of Schizophrenia, Schizophreniform, or schizoaffective disorder as per DSM-V criteria
• Within five years of onset of illness
• Treated with any antipsychotic agent except clozapine at an adequate, stable dose for at least 8 weeks.
• A score of at least 4 (moderate) on at least one BPRS negative symptom item.

You may not qualify if…

• Serious or unstable medical illness
• Pregnant or nursing
• Abuse of substances except nicotine in the previous 6 weeks (excluding cannabis use)
• Positive urine toxicology at screening
• Experiencing serious suicidal or homicidal ideation within six months
• Treatment with clozapine

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States
• New York University Langone Medical Center/ Bellevue Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.